 A novel allergy vaccine Ragweed MATAMPL has been developed for the prevention or relief of allergic symptoms caused by a variety of pollens. Ragweed MATAMPL, which contains the allergens of ragweed chemically modified by glutaraldehyde adsorbed onto L-tyrosine with the addition of the adjuvant monophosphoryl lipid A MPL, is being evaluated for the specific treatment of ragweed seasonally induced allergic rhinitis. Ragweed MATAMPL is intended for use as a pre-seasonal therapeutic allergy vaccine in patients with proven seasonal allergic rhinitis and conjunctivitis due to IgE mediated allergy to ragweed. This novel vaccine formulation is designed to provide a vaccine that will be efficacious with only four escalating dose injections, in contrast to the longer schedules currently in use. 